KR20230125806A - 선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드 - Google Patents

선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드 Download PDF

Info

Publication number
KR20230125806A
KR20230125806A KR1020237023945A KR20237023945A KR20230125806A KR 20230125806 A KR20230125806 A KR 20230125806A KR 1020237023945 A KR1020237023945 A KR 1020237023945A KR 20237023945 A KR20237023945 A KR 20237023945A KR 20230125806 A KR20230125806 A KR 20230125806A
Authority
KR
South Korea
Prior art keywords
ser
leu
lys
arg
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237023945A
Other languages
English (en)
Korean (ko)
Inventor
카르골 마르크 구엘
가르시아 아벤치아 산체즈-메히아스
마스미타 마리아 팔라레스
Original Assignee
우니베르시타트 폼페우 파브라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니베르시타트 폼페우 파브라 filed Critical 우니베르시타트 폼페우 파브라
Publication of KR20230125806A publication Critical patent/KR20230125806A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237023945A 2020-12-16 2021-12-16 선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드 Pending KR20230125806A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20214691 2020-12-16
EP20214691.6 2020-12-16
EP21209721 2021-11-22
EP21209721.6 2021-11-22
PCT/EP2021/086333 WO2022129430A1 (en) 2020-12-16 2021-12-16 Therapeutic lama2 payload for treatment of congenital muscular dystrophy

Publications (1)

Publication Number Publication Date
KR20230125806A true KR20230125806A (ko) 2023-08-29

Family

ID=79269765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023945A Pending KR20230125806A (ko) 2020-12-16 2021-12-16 선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드

Country Status (7)

Country Link
US (1) US20250269057A1 (https=)
EP (1) EP4263818A1 (https=)
JP (1) JP2023553701A (https=)
KR (1) KR20230125806A (https=)
AU (1) AU2021399929A1 (https=)
CA (1) CA3202411A1 (https=)
WO (1) WO2022129430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118185901B (zh) * 2022-12-12 2025-03-21 北京精缮生物科技有限责任公司 一种PBase蛋白、融合蛋白、核酸和基因整合系统及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
JP5813321B2 (ja) 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
JP2018513681A (ja) * 2015-03-31 2018-05-31 エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. 細胞または生物のゲノムへのＤＮＡ配列の標的化組み込みのためのＣａｓ９レトロウイルスインテグラーゼおよびＣａｓ９レコンビナーゼ系
US20200095579A1 (en) * 2017-02-22 2020-03-26 Crispr Therapeutics Ag Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disorders
WO2018175872A1 (en) * 2017-03-24 2018-09-27 President And Fellows Of Harvard College Methods of genome engineering by nuclease-transposase fusion proteins
US20220235379A1 (en) * 2019-06-11 2022-07-28 Universitat Pompeu Fabra Targeted gene editing constructs and methods of using the same

Also Published As

Publication number Publication date
EP4263818A1 (en) 2023-10-25
AU2021399929A1 (en) 2023-07-06
CA3202411A1 (en) 2022-06-23
JP2023553701A (ja) 2023-12-25
US20250269057A1 (en) 2025-08-28
WO2022129430A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
AU2018383712B2 (en) Cpf1-related methods and compositions for gene editing
KR102544051B1 (ko) 인간화된 ttr 유전자좌를 포함하는 비인간 동물 및 사용 방법
KR102500531B1 (ko) 헤모글로빈병증 치료용 글로빈 유전자 치료법
KR20230019843A (ko) 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
JP4493492B2 (ja) 脊椎動物における遺伝子移入のためのトランスポゾンベクターであるＦｒｏｇＰｒｉｎｃｅ
KR20210143230A (ko) 뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
KR20210125560A (ko) 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용한 질환-관련 유전자의 스플라이스 수용체 부위 파괴
KR20200132849A (ko) CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
KR20210082205A (ko) 레트로바이러스 인테그라제-Cas9 융합 단백질을 이용한 유도된 비상동 DNA 삽입에 의한 게놈 편집
KR102915369B1 (ko) X-연관 연소 망막층간분리 치료법을 위한 crispr 및 aav 전략
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
KR20210151785A (ko) 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
AU2019403015B2 (en) Nuclease-mediated repeat expansion
KR20220113940A (ko) Rna 분자의 고-효율 재조합을 위한 조성물 및 방법
CN113874510A (zh) 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法
KR20220062079A (ko) 지질 나노입자에 의해 전달되는 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
AU2020289581B2 (en) Non-human animals comprising a humanized albumin locus
JP2024540390A (ja) 可動因子及びそのキメラ構築物
KR20230125806A (ko) 선천성 근이영양증의 치료를 위한 치료용 lama2 페이로드
AU2018286393A2 (en) Genome editing system for repeat expansion mutation
KR20240000580A (ko) 레트로바이러스 인테그라제-Cas 융합 단백질을 이용한 직접 비상동 DNA 삽입에 의한 게놈 편집 및 치료 방법
CN117043324A (zh) 用于治疗先天性肌营养不良的治疗性lama2载荷
RU2833486C1 (ru) Стратегии crispr и aav для терапии х-сцепленного ювенильного ретиношизиса
RU2815514C2 (ru) Животные, отличные от человека, содержащие гуманизированный локус альбумина
RU2812852C2 (ru) Невирусные днк-векторы и варианты их применения для экспрессии терапевтического средства на основе фактора viii (fviii)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230713

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241211

Comment text: Request for Examination of Application